USFDA inspects Aurobindo Pharma's facility for 3rd time this month
Aurobindo Pharma just got four new "observations" from the US FDA after an inspection at its Eugia Pharma Specialities Unit I (Feb 16-27, 2026).
This makes it the third time this month that the company's facilities have caught the FDA's eye.
Two other Aurobindo units inspected earlier in February
Earlier in February, two other Aurobindo units—Eugia Unit III in Hyderabad and the oral solid dosage manufacturing unit of Aurobindo Pharma near Hyderabad (reported to have received nine observations)—were also inspected, racking up a total of 20 procedural observations.
The FDA seems to be keeping a close watch on how things are run at Aurobindo.
No FDA approval reported for everolimus tablets
Aurobindo told stock exchanges there's no hit to their finances or operations and promised to respond to the FDA on time.
The source does not report any FDA approval for Everolimus Tablets or any product launch timeline; the article only reports observations and that Aurobindo said there is no impact and it will respond to the regulator.